[Cl:1][C:2]1[S:6][C:5]([C:7]2[N:11]3[CH2:12][C@H:13]4[NH:17][C@@H:16]([C:10]3=[N:9][N:8]=2)[CH2:15][CH2:14]4)=[CH:4][CH:3]=1.[Cl:18][C:19]1[C:20]([C:28]([F:31])([F:30])[F:29])=[N:21][CH:22]=[CH:23][C:24]=1[C:25](O)=[O:26].C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.Cl>C(Cl)Cl>[Cl:1][C:2]1[S:6][C:5]([C:7]2[N:11]3[CH2:12][C@H:13]4[N:17]([C:25]([C:24]5[CH:23]=[CH:22][N:21]=[C:20]([C:28]([F:31])([F:29])[F:30])[C:19]=5[Cl:18])=[O:26])[C@@H:16]([C:10]3=[N:9][N:8]=2)[CH2:15][CH2:14]4)=[CH:4][CH:3]=1To a solution of (6S,9R)-3-(5-chlorothiophen-2-yl)-6,7,8,9-tetrahydro-5H-6,9-epimino[1,2,4]triazolo[4,3-a]azepine (Example 55, step b) (35 mg, 0.132 mmol) in DCM (2 mL) was added 3-chloro-2-(trifluoromethyl)-4-pyridinecarboxylic acid (30 mg, 0.132 mmol) followed by HOBt (12 mg, 0.09 mmol), EDCl (38 mg, 0.197 mmol) and TEA (0.04 mL, 0.263 mmol). The reaction was stirred at room temperature overnight and then loaded directly on a SiO2 column eluting with IPA/EtOAc to afford the title compound (53 mg, 85%). MS (ESI): mass calcd. C18H12Cl2F3N5OS, 473.01; m/z found, 473.8 [M+H]+. 1H NMR (500 MHz, CDCl3): 8.75-8.59 (m, 1H), 7.68-7.30 (m, 1H), 7.26-7.13 (m, 1H), 7.03-6.92 (m, 1H), 5.46-5.31 (m, 1H), 4.98-4.87 (m, 1H), 4.65-4.50 (m, 1H), 4.25-3.94 (m, 1H), 2.63-2.23 (m, 3H), 2.00-1.86 (m, 1H).